β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
about
An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cellsSalinomycin as a drug for targeting human cancer stem cellsAberrant Wnt Signaling in LeukemiaMammary Development and Breast Cancer: A Wnt PerspectiveG Protein-Coupled Receptor Signaling in Stem Cells and CancerRecent progress toward epigenetic therapies: the example of mixed lineage leukemiaCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkSurvival regulation of leukemia stem cellsA novel application of furazolidone: anti-leukemic activity in acute myeloid leukemiaAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Cancer stem cells: a systems biology view of their role in prognosis and therapyChromatin modifications as therapeutic targets in MLL-rearranged leukemia.Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinomaABC transporters in CSCs membranes as a novel target for treating tumor relapse.Protein network study of human AF4 reveals its central role in RNA Pol II-mediated transcription and in phosphorylation-dependent regulatory mechanisms.CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.Tackling the cancer stem cells - what challenges do they pose?NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemiaHeterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors.Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemiaKRas(G12D)-evoked leukemogenesis does not require β-catenin.Differential niche and Wnt requirements during acute myeloid leukemia progressionPre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cellsTRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185Prostate cancer stem cell biology.Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma.β-Arrestin2 mediates the initiation and progression of myeloid leukemia.SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.The 14-3-3σ/GSK3β/β-catenin/ZEB1 regulatory loop modulates chemo-sensitivity in human tongue cancerCritical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.Utilisation of nanoparticle technology in cancer chemoresistance.γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-cateninThe NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling
P2860
Q21245772-5FE5C23F-7E25-4E91-9AA9-DEAC60884678Q21285139-377031F8-87E6-43E6-AD52-9304B71892B4Q26738411-787CF508-5518-403B-A7A3-E6F0C60558A1Q26740086-ECCAC8AF-FE41-4680-B7C2-B8C8ABF7B9ECQ26853233-09948998-25B2-46A7-A3AE-2DD0B0DC6D2BQ26863577-AF9A8FD7-6AFB-48C6-A7B4-6701949D7D4FQ26865911-D9EB7C0B-B612-47CF-B349-7B96CFCF857CQ28271278-FA29F2E4-1196-4681-B328-CE1C4F8BF477Q28535230-02B6CE0A-4407-4992-BABD-3944AEA12DC1Q30275229-C4FA15CE-AE18-45C8-BAE5-46861AC43E08Q33569712-166D9F42-EE49-4718-9515-3D34DD190646Q33666543-32DE53E6-2101-4D42-84D0-246DF5AB988CQ33820347-F3375DBF-6572-43A3-AFD2-D0F24635A663Q33879326-966CD749-F4E6-4C3D-A2A8-B349291F05C3Q33901300-CA39A479-EF8B-4CAA-AC55-223EFCA38BDDQ33926141-37E8219F-8D4F-4B37-B499-C93E7FB78A16Q34156754-FADECA8C-39D9-45A0-9174-AA3DBB5D8D40Q34310186-C2F37627-30A6-42E1-A64F-BA39176C242CQ34348631-95D87662-FEE8-4DF3-B3EE-904CD09FAB6AQ34523263-694C9DE8-0A25-43A9-93F3-97DA80CEF136Q34551220-83438671-245F-4941-8EDF-D1CC9E0CAC54Q34905557-8500D7B7-6103-40E7-AAE2-C1ADC2B5898CQ34961818-F4D7C390-9696-45DA-9BF5-526851056181Q35018755-775ECCF8-028F-4BCC-8CD5-9743DA850B2EQ35056301-5E07B939-3B7E-4220-BD24-443E550DA915Q35201278-08B91F45-5893-4753-A241-DBFD0678C955Q35212397-2AAE8D57-1690-4F2C-B951-F1C9C04E87D1Q35685058-A1EAA2AE-0412-4060-A666-EDCD0E80B780Q35854054-4B82FF9E-ECE5-4B31-BC1E-6968FB711EC4Q35903584-19D7F8A3-049D-431F-BDFD-F2F166EF84D7Q36104764-04146A5D-F7E0-4FDA-A48F-FB7BE551A369Q36140375-E3AAA29F-049C-4C18-B6F3-488349D28108Q36205970-D5779764-3D3E-480B-9539-834A332DC0E7Q36278046-E99745BA-30B2-43C6-9616-44F2C72F14F2Q36299623-64944709-F0A5-4650-A337-1410C3EA0B27Q36414274-4F9D766C-F1EF-40D4-B4A1-9BA1154B60DBQ36421258-8846056E-D91D-472F-991A-D84A359B5AB1Q36732802-1E11662B-E79D-4199-A149-C0BFC52BC70AQ36876973-4F14B302-CDFE-424D-B13C-74513358EC1EQ37101484-B1A2ADAA-35AF-4DE6-8812-033A78346270
P2860
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@en
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@nl
type
label
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@en
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@nl
prefLabel
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@en
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@nl
P2093
P1433
P1476
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
@en
P2093
Arnaud Gandillet
Bernd B Zeisig
Chi Wai Eric So
Dominique Bonnet
Jenny Yeung
Maria Teresa Esposito
P304
P356
10.1016/J.CCR.2010.10.032
P577
2010-12-01T00:00:00Z